Cue Biopharma Inc’s recent filing unveils that its CHIEF EXECUTIVE OFFICER PASSERI DANIEL R acquired Company’s shares for reported $30900.0 on Dec 16 ’24. In the deal valued at $1.03 per share,30,000 shares were bought. As a result of this transaction, PASSERI DANIEL R now holds 164,578 shares worth roughly $0.17 million.
Jefferies initiated its Cue Biopharma Inc [CUE] rating to a Buy in a research note published on March 13, 2024; the price target was $6. Piper Sandler began covering CUE with “an Overweight” recommendation on November 21, 2022. H.C. Wainwright started covering the stock on January 13, 2022. It rated CUE as “a Buy”.
Price Performance Review of CUE
On Friday, Cue Biopharma Inc [NASDAQ:CUE] saw its stock fall -0.98% to $1.01. Over the last five days, the stock has gained 7.45%. Cue Biopharma Inc shares have fallen nearly -61.74% since the year began. Nevertheless, the stocks have fallen -63.14% over the past one year. While a 52-week high of $3.20 was reached on 01/12/24, a 52-week low of $0.45 was recorded on 09/26/24. SMA at 50 days reached $1.3058, while 200 days put it at $1.2646.
Levels Of Support And Resistance For CUE Stock
The 24-hour chart illustrates a support level at 0.9700, which if violated will result in even more drops to 0.9300. On the upside, there is a resistance level at 1.0700. A further resistance level may holdings at 1.1300. The Relative Strength Index (RSI) on the 14-day chart is 41.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0277, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 70.96%. Stochastics %K at 33.81% indicates the stock is a holding.
How much short interest is there in Cue Biopharma Inc?
A steep rise in short interest was recorded in Cue Biopharma Inc stocks on 2024-10-31, dropping by -2.02 million shares to a total of 1.78 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 3.8 million shares. There was a decline of -113.39%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 03, 2022 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $28 price target.
